# US 8,465,741 B2 · Antibodies and methods for making and using them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,741 B2
- Document ID: US8465741B2
- Status: Granted
- Kind: B2
- Application number: 11/855,943
- Filed: 2007-09-14
- Published: 2010-04-29
- Granted: 2013-06-18
- Earliest claimed: 2006-12-20
- Assignees: MMRGlobal, Inc.
- Applicants: Gerhard Frey; Bruce E. Kimmel; Abraham Anderson
- Inventors: Gerhard Frey; Bruce E. Kimmel; Abraham Anderson
- Web page: https://patentgrep.com/patent/US8465741B2

## CPC

- C07K 16/2887: {against CD20}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/06: Antianaemics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/02: Antidotes
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/567: Framework region [FR]
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/734: Complement-dependent cytotoxicity [CDC]
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.

## Claims

### Claim 1

An antibody or antigen-binding fragment thereof comprising at least one variable region having a combination of:
(1) light chain BD22084 (SEQ ID NO:225) and heavy chain BD20332 (SEQ ID NO:138);
(2) light chain BD22085 (SEQ ID NO:232) and heavy chain BD20335 (SEQ ID NO:143);
(3) light chain BD22086 (SEQ ID NO:227) and heavy chain BD20335 SEQ ID NO:143);
(4) light chain BD22088 (SEQ ID NO:229) and heavy chain BD20337 (SEQ ID NO:148);
(5) light chain BD22087 (SEQ ID NO:240) and heavy chain BD20335 (SEQ ID NO:143);
(6) light chain BD22089 (SEQ ID NO:243) and heavy chain BD20335 (SEQ ID NO:143);
(7) light chain BD22090 (SEQ ID NO:234) and heavy chain BD20337 (SEQ ID NO:148);
(8) light chain BD22095 (SEQ ID NO:244) and heavy chain BD20337 (SEQ ID NO:148);
(9) light chain BD22091 (SEQ ID NO:242) and heavy chain BD20337 (SEQ ID NO:148);
(10) light chain BD22108 (SEQ ID NO:230) and heavy chain BD20337 (SEQ ID NO:148);
(11) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20338 (SEQ ID NO:149);
(12) light chain BD22094 (SEQ ID NO:231) and heavy chain BD20337 (SEQ NO: 148);
(13) light chain BD22096 (SEQ ID NO:241) and heavy chain BD20337 (SEQ ID NO:148);
(14) light chain BD22092 (SEQ ID NO:235) and heavy chain BD20337 (SEQ ID NO:148);
(15) light chain BD22102 (SEQ ID NO:248) and heavy chain BD20337 (SEQ ID NO: 148);
(16) light chain BD22097 (SEQ ID NO:246) and heavy chain BD20335 (SEQ ID NO:143);
(17) light chain BD22104 (SEQ ID NO:239) and heavy chain BD20337 SEQ ID NO:148);
(18) light chain BD22085 (SEQ ID NO:232) and heavy chain BD20339 (SEQ ID NO:150);
(19) light chain BD22107 (SEQ ID NO:226) and heavy chain BD20339 (SEQ ID NO: 150);
(20) light chain BD22100 (SEQ ID NO:236) and heavy chain BD20335 (SEQ ID NO:143);
(21) light chain BD22103 (SEQ ID NO:228) and heavy chain BD20337 SEQ ID NO:148);
(22) light chain BD22105 (SEQ ID NO:237) and heavy chain BD20337 (SEQ ID NO:148);
(23) light chain BD22101 (SEQ ID NO:247) and heavy chain BD20335 (SEQ ID NO:143);
(24) light chain BD22106 (SEQ ID NO:245) and heavy chain BD20333 (SEQ ID NO:142);
(25) light chain BD22108 (SEQ ID NO:230) and heavy chain BD20338 (SEQ ID NO:149);
(26) light chain BD22109 (SEQ ID NO:233) and heavy chain BD20341 (SEQ ID NO:154); or
(27) light chain BD22111 (SEQ ID NO:238) and heavy chain BD20336 (SEQ ID NO:144).

### Claim 2 (depends on 1)

The antigen binding antibody fragment of claim 1, wherein the antibody fragment is an Fab fragment, an Fab′ fragment, an F(ab′), fragment, a single-chain antibody, an Fv fragment, an scFv fragment, an antibody mimetic, an Fd fragment, or an Fd′ fragment.

### Claim 3 (depends on 2)

The antigen binding antibody fragment of claim 2, wherein the antibody fragment is fused to an Fc.

### Claim 4 (depends on 1)

A recombinant, synthetic or isolated antibody having a structure comprising at least one variable region combination of claim 1.

### Claim 5 (depends on 1)

A chimeric antibody or antigen binding fragment thereof comprising at least one variable region combination of claim 1.

### Claim 6 (depends on 5)

A chimeric antigen binding antibody fragment of claim 5, wherein the chimeric antibody fragment is a chimeric Fab, a chimeric Fab′, a chimeric F(ab′)2, a chimeric single-chain antibody, a chimeric Fv, a chimeric scFv, an antibody mimetic, a chimeric Fd, or a chimeric Fd′.

### Claim 7 (depends on 1)

A pharmaceutical composition or formulation comprising:
(a) an antibody or antigen binding fragment thereof of claim 1.

### Claim 8 (depends on 7)

The pharmaceutical composition or formulation of claim 7, further comprising a pharmaceutically acceptable carrier or excipient.